Clinical Insights in Myelofibrosis: Addressing Unmet Needs & Advancing Outcomes
Panelists discuss optimizing treatment strategies for higher-risk myelofibrosis patients. They focus on managing thrombocytopenia, anemia, and ruxolitinib failure while exploring the role of JAK inhibitors and sequencing therapies.
EP. 1: Clinical Perspectives: Firstline Treatment Landscape in Higher-Risk MF
November 27th 2024Panelists discuss how frequently patients with newly diagnosed myelofibrosis present with moderate or severe thrombocytopenia or both anemia and thrombocytopenia. They discuss how these factors and other disease characteristics like spleen size and constitutional symptoms influence their treatment approach and selection of JAK inhibitors.
